|
ATE180280T1
(de)
*
|
1991-03-05 |
1999-06-15 |
Wellcome Found |
Expression rekombinanter proteine in attenuierten bakterien
|
|
US5961974A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
|
US7405270B2
(en)
*
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
EP0897983B1
(en)
|
1991-10-25 |
2003-05-07 |
Immunex Corporation |
Antibody against CD40-L
|
|
US5981724A
(en)
*
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US5716805A
(en)
*
|
1991-10-25 |
1998-02-10 |
Immunex Corporation |
Methods of preparing soluble, oligomeric proteins
|
|
US5962406A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
EP0659086B1
(en)
*
|
1992-09-04 |
1998-11-11 |
The University of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
US5540926A
(en)
*
|
1992-09-04 |
1996-07-30 |
Bristol-Myers Squibb Company |
Soluble and its use in B cell stimulation
|
|
US5565321A
(en)
*
|
1993-01-22 |
1996-10-15 |
Immunex Corporation |
Detection of mutations in a CD40 ligand gene
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
DE69534595T2
(de)
*
|
1994-04-28 |
2006-05-24 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
|
|
DE69622259T2
(de)
|
1995-03-01 |
2003-03-27 |
Immunex Corp., Seattle |
Cd40 bindendes protein zur stimulierung der immunantwort
|
|
KR100453314B1
(ko)
|
1995-06-07 |
2004-12-17 |
임뮤넥스 코포레이션 |
Cd40l 돌연변이 단백질
|
|
US6479258B1
(en)
*
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6713279B1
(en)
*
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6306387B1
(en)
*
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
*
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
JP2001526241A
(ja)
|
1997-12-19 |
2001-12-18 |
イミュネックス・コーポレーション |
Ｈｉｖ感染に対する感受性を低下させるための方法
|
|
GB9806449D0
(en)
*
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
*
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
EP1108034B1
(en)
*
|
1998-09-04 |
2008-08-06 |
Emergent Product Development UK Limited |
Attenuated salmonella spi2 mutants as antigen carriers
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
CA2369820A1
(en)
|
1999-04-16 |
2000-10-26 |
Frank Dicker |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US7803765B2
(en)
*
|
1999-05-05 |
2010-09-28 |
Phylogica Limited |
Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
|
|
WO2001026608A2
(en)
*
|
1999-10-14 |
2001-04-19 |
Ledbetter Jeffrey A |
Dna vaccines encoding antigen linked to a domain that binds cd40
|
|
MXPA00012796A
(es)
*
|
1999-12-28 |
2002-05-23 |
Akzo Nobel Nv |
Vacuna de salmonella.
|
|
DE60136334D1
(en)
*
|
2000-02-02 |
2008-12-11 |
Us Health |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
|
BR0109322A
(pt)
*
|
2000-03-17 |
2002-12-10 |
Upjohn Co |
Materiais e métodos de vacina de salmonella
|
|
GB0015426D0
(en)
*
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
US20030165538A1
(en)
|
2000-06-26 |
2003-09-04 |
Maxygen Incorporated |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
AU2002308732A1
(en)
|
2001-05-15 |
2002-11-25 |
Ortho-Mcneil Pharmaceutical, Inc. |
Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
|
|
ZA200400479B
(en)
*
|
2001-07-06 |
2006-05-31 |
Abic Biolog Lab Teva |
Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
|
|
BR0210850A
(pt)
*
|
2001-07-06 |
2004-12-07 |
Biolog Lab Teva Ltd |
ácidos nucléicos que codificam um antìgeno de 250 kda recombinante de esporozoìtos/merozoìtos de eimeria máxima e seus usos
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
WO2003028441A1
(en)
|
2001-10-02 |
2003-04-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gene therapy for the prevention of autoimmune disease
|
|
US7238499B2
(en)
*
|
2001-12-21 |
2007-07-03 |
Immunex Corporation |
Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids
|
|
WO2003067991A1
(en)
*
|
2002-02-13 |
2003-08-21 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
|
US6923958B2
(en)
*
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
EP1499191B1
(en)
*
|
2002-04-15 |
2012-05-09 |
Washington University in St. Louis |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
*
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20050181994A1
(en)
*
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US20060014248A1
(en)
*
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US7754209B2
(en)
*
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
EP1673389A2
(en)
|
2003-10-10 |
2006-06-28 |
Xencor Inc. |
Novel variants of cd40l protein
|
|
CA2548347A1
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
*
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
WO2006042177A2
(en)
|
2004-10-07 |
2006-04-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
WO2006130525A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
|
EP1949913B1
(en)
|
2005-10-07 |
2010-06-02 |
Proyecto de Biomedicina Cima, S.L. |
Immunostimulatory combination for the prophylactics and treatment of hepatitis c
|
|
WO2007056266A2
(en)
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
Cd40 ligand fusion protein vaccine
|
|
DE102005054643B3
(de)
|
2005-11-10 |
2007-02-15 |
Assa Abloy Sicherheitstechnik Gmbh |
Schließzylinder
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
CU23576A1
(es)
*
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
*
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US8802419B2
(en)
*
|
2006-03-02 |
2014-08-12 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
FR2898905B1
(fr)
*
|
2006-03-24 |
2008-05-09 |
Rhodia Recherches & Tech |
Composition polyisocyanate a proprietes anti-chocs ameliorees
|
|
US20090246220A1
(en)
*
|
2006-08-28 |
2009-10-01 |
Ertl Hildegund C J |
Constructs for enhancing immune responses
|
|
US8604178B2
(en)
*
|
2006-09-18 |
2013-12-10 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses
|
|
WO2008109825A2
(en)
|
2007-03-08 |
2008-09-12 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
CN101024076B
(zh)
*
|
2007-03-29 |
2010-08-18 |
中国农业大学 |
球虫的新用途
|
|
WO2009007120A2
(en)
*
|
2007-07-10 |
2009-01-15 |
Apogenix Gmbh |
Tnf superfamily collectin fusion proteins
|
|
US9125854B2
(en)
*
|
2007-10-30 |
2015-09-08 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to flagellated bacterium
|
|
NZ601880A
(en)
*
|
2007-11-01 |
2013-12-20 |
Univ Arkansas |
Compositions and methods of enhancing immune responses to eimeria
|
|
HUE025236T2
(en)
*
|
2008-07-21 |
2016-03-29 |
Apogenix Gmbh |
TNFSF single chain molecules
|
|
US8316310B2
(en)
|
2008-08-05 |
2012-11-20 |
International Business Machines Corporation |
System and method for human identification proof for use in virtual environments
|
|
PL2184229T3
(pl)
*
|
2008-11-11 |
2013-04-30 |
Agustawestland Spa |
Wirnik śmigłowca
|
|
US20100150958A1
(en)
*
|
2008-12-15 |
2010-06-17 |
Vectogen Pty Ltd. |
Methods and Compositions for Use of a Coccidiosis Vaccine
|
|
PT2525817T
(pt)
*
|
2010-01-21 |
2017-10-24 |
Texas A & M Univ Sys |
Vetores de vacina e métodos para o aumento de respostas imunes
|
|
PT2771022T
(pt)
*
|
2011-10-11 |
2020-09-14 |
Viela Bio Inc |
Suportes derivados de tn3 específicos para cd40l e métodos de uso dos mesmos
|
|
US20140079704A1
(en)
*
|
2012-09-11 |
2014-03-20 |
The Texas A&M University System |
BI-Specific Diabodies For Masking And Targeting Vaccines
|
|
MX380857B
(es)
*
|
2012-10-29 |
2025-03-11 |
Univ Arkansas |
Nuevos coadyuvantes y sistemas de administración para mucosas.
|
|
PT2956165T
(pt)
*
|
2013-02-14 |
2019-11-29 |
Texas A & M Univ Sys |
Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria
|
|
JP6530742B2
(ja)
*
|
2013-03-15 |
2019-06-12 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー |
腸内病原体の免疫応答を強化する組成物及び方法
|
|
JP2017523136A
(ja)
*
|
2014-06-05 |
2017-08-17 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー |
抗体誘導ワクチン及び迅速な成熟免疫応答の発生のための使用方法
|
|
US20160090603A1
(en)
*
|
2014-09-30 |
2016-03-31 |
Sandia Corporation |
Delivery platforms for the domestication of algae and plants
|
|
KR20230148844A
(ko)
*
|
2016-03-29 |
2023-10-25 |
유니버시티 오브 써던 캘리포니아 |
암을 표적하는 키메라 항원 수용체
|
|
WO2017205742A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Abbvie Biotherapeutics Inc. |
Anti-cd40 antibodies and their uses
|
|
IL308824A
(en)
*
|
2016-08-17 |
2024-01-01 |
Factor Bioscience Inc |
Nucleic acid products and methods of administration thereof
|